iptacopan

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM.

Iptacopan hydrochloride (LNP023 hydrochloride) is a small-molecule inhibitor and a complement factor B inhibitor (IC50 = 10 nM, KD = 7.9 nM) with high selectivity, oral activity, and cell permeability, used for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, IgA nephropathy, and C3 glomerulopathy.

Iptacopan (LNP023) TFA is a potent, orally active, and highly selective factor B inhibitor, exhibiting an IC50 of 10 nM and a KD of 7.9 nM. It acts proximally in the complement cascade to prevent red blood cell destruction (hemolysis) in paroxysmal nocturnal hemoglobinuria (PNH) and renal cell damage in IgA nephropathy (IgAN) and C3 glomerulopathy (C3G). Iptacopan TFA is utilized in the study of complement-mediated diseases, particularly PNH, IgAN, and C3G.

Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor.

Dapivirine HCl is the salt form of Dapivirine, also known as TMC120, a non-nucleoside inhibitor for HIV reverse transcriptase with IC50 of 24 nM. The HIV-1 replication inhibitor dapivirine (DPV) is one of the most promising drug candidates being used in topical microbicide products for prevention of HIV-1 sexual transmission.